Noile-Immune Biotech Inc.
4893.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥7,360,580 | ¥8,791,263 | ¥28,005,120 | ¥29,400,560 |
| - Cash | ¥4,670,000 | ¥5,555,691 | ¥4,520,997 | ¥4,140,558 |
| + Debt | ¥0 | ¥0 | ¥0 | ¥0 |
| Enterprise Value | ¥2,690,580 | ¥3,235,572 | ¥23,484,123 | ¥25,260,002 |
| Revenue | ¥7,587 | ¥316,818 | ¥625,783 | ¥100,732 |
| % Growth | -97.6% | -49.4% | 521.2% | – |
| Gross Profit | ¥7,392 | ¥314,561 | ¥618,706 | ¥77,833 |
| % Margin | 97.4% | 99.3% | 98.9% | 77.3% |
| EBITDA | -¥1,069,182 | -¥775,391 | -¥106,345 | -¥767,511 |
| % Margin | -14,092.3% | -244.7% | -17% | -761.9% |
| Net Income | -¥964,455 | -¥1,130,014 | -¥386,622 | -¥795,035 |
| % Margin | -12,711.9% | -356.7% | -61.8% | -789.3% |
| EPS Diluted | -22.26 | -27.25 | -9.87 | -19.33 |
| % Growth | 18.3% | -176.1% | 48.9% | – |
| Operating Cash Flow | -¥887,809 | -¥873,076 | -¥107,176 | -¥777,140 |
| Capital Expenditures | ¥0 | ¥0 | ¥0 | ¥0 |
| Free Cash Flow | -¥887,809 | -¥873,076 | -¥107,176 | -¥777,140 |